Affymax, Inc.

ADEPTIDE

Pharmaceutical preparations for the treatment of anemia; pharmaceutical preparations for the prevention and treatment of ischemia;

AFFYMAX

research and product development services for others in the field of chemicals and reagents for use as diagnostics, therapeutics, herbicides, cytotoxic agents, and other utilities, and chemical screening and diagnostic services for others;

AFFYMAX

AFFY MAX;Color is not claimed as a feature of the mark.;Scientific and medical research for the purposes of new drug discovery;

AFFYMAX

AFFY MAX;Color is not claimed as a feature of the mark.;Scientific and medical research for the purposes of new drug discovery;

AFFYMAX

Pharmaceuticals for use in stimulating human blood cell production; pharmaceuticals for the treatment of cancer, anemia, ischemia, myocardial infarction, congestive heart failure, renal failure, anoxia-induced cellular degeneration, hypoxia-induced cellular degeneration and stroke;

AFFYMAX

Pharmaceuticals for use in stimulating human blood cell production; pharmaceuticals for the treatment of cancer, anemia, ischemia, myocardial infarction, congestive heart failure, renal failure, anoxia-induced cellular degeneration, hypoxia-induced cellular degeneration and stroke;

AMAXYN

pharmaceutical preparations for the treatment of diseases and ailments associated with immunosupression;

AVIXIS

pharmaceutical preparations for use in stimulating human blood cell production;

COMMUNI K

Informational services in the nature of online provision of non-downloadable publications, namely, educational materials with respect to renal disease;The mark consists of the formative COMMUNI in dark blue followed by a red dot and the letter K in dark blue below a blue-outlined quote bubble in which overlapping stylized images of kidneys in red and blue are displayed. The color white is for background purposes only and is not claimed as a feature of the mark.;Printed educational materials in the field of renal disease;The color(s) blue and red is/are claimed as a feature of the mark.;

COMMUNI K

Informational services in the nature of online provision of non-downloadable publications, namely, educational materials regarding renal disease;The mark consists of the formative COMMUNI followed by a dot and the letter K below a quote bubble in which overlapping stylized kidney designs are displayed.;Educational materials in the field of renal disease;Color is not claimed as a feature of the mark.;

HEMATIDE

Pharmaceutical preparations for use in stimulating human blood cell production;

HEMATIDE

Pharmaceutical preparations for use in stimulating human blood cell production;

HEMATIDE

Pharmaceuticals for use in stimulating human blood cell production; pharmaceuticals for the treatment of cancer, anemia, ischemia, myocardial infarction, congestive heart failure, renal failure, anoxia-induced cellular degeneration, hypoxia-induced cellular degeneration and stroke;

HEMOMAX

pharmaceutical preparations;

INNOTIDE

Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases, renal failure and myocardial infarction;

RENAL RESPOND

Patient support services in the nature of administration of patient reimbursement programs;Health and medical information services;RENAL;

TANDEM

Education collaboration services, namely, organizing and hosting events for health care providers and patients in the renal community to collaborate and share medical information to improve the treatment of anemia due to chronic kidney disease;The mark consists of the stylized wording TANDEM with the letters TANDE in red and the letter M with two circles above the letter, the left half of the letter is in blue and the right half is in red, the letter resembles a drawing of two people holding hands.;The color(s) red and blue is/are claimed as a feature of the mark.;Providing health information to health care providers and patients in the renal community on the treatment of anemia due to chronic kidney disease;